# The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

> **NCT00937131** · PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 40 (actual)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura (TTP)

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00937131
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937131, "The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00937131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*